A Beacon alternative — when you need the read.

Of everything a clinical-stage oncology company shortlists, Beacon is the one that overlaps most with what Prognyx watches — and the one where the difference in form matters most. Both are oncology-native. Only one of them is a database.

What Beacon actually is

Beacon Intelligence, formerly Beacon Targeted Therapies and part of Hanson Wade, publishes manually curated drug-development databases organised by modality and by disease area. Alongside modules such as ADC, bispecific, cell therapy, checkpoint, cancer vaccine, oncolytic viruses, RNA and targeted protein degradation, it publishes a dedicated oncology database spanning preclinical and clinical programmes with drug, trial, company and deal records, proprietary ontologies for filtering, and APIs for structured access.

Its differentiating claim is curation by scientists rather than automated ingestion, with daily updates and a granularity aimed at benchmarking differentiation — trial arms, combination designs, endpoints, efficacy and toxicity. In a field of all-of-pharma platforms, a database built specifically for complex oncology therapeutics is a real and unusual thing, and this page does not argue otherwise.

What Prognyx is

Prognyx is not a database and does not compete on coverage. It is an outsourced oncology competitive-intelligence function: one analyst watching the competitive set you name and delivering briefs on what changed, what it means for your asset and what to do — each claim traced to the primary record.

When Beacon is the better buy

• You have scientists who want the underlying data. Translational and preclinical teams benchmarking a construct against a whole modality need records and filters, not a narrative. Prognyx does not hold that dataset.
• Preclinical depth matters to you. Prognyx's watch is strongest on registered trials, regulatory actions and disclosures. A curated preclinical landscape is a different capability.
• You need structured, machine-readable output. If the plan is to pipe competitive data into your own analytics, an API beats a document — this is not close.
• Your question spans a whole modality. "Every ADC in development against this target" is a query. It is exactly what a curated modality database is for.
• You work outside oncology too — Beacon publishes databases in other disease areas; Prognyx will decline the work rather than take it.

When Prognyx is the better buy

• Nobody will run the queries. Curated depth only pays if someone sits with it weekly. Where competitive intelligence is an evening task, the constraint is analyst hours, not data quality.
• You need the judgement call, not the landscape. Whether a competitor's subgroup result changes your comparator assumption is a reading problem. No filter answers it.
• The output has to travel. A brief goes to the board, the co-founder or a prospective partner as-is. A dashboard view does not.
• You want the primary record cited, not summarised. Prognyx links the NCT, the filing, the abstract, so a reader can check the work rather than trust a row.
• You want someone accountable. Here that is Rali Filali, by name, with the method published.

The cost question, honestly

Beacon does not publish list pricing; access is arranged through a demonstration. This page invents no figure. The shape is a modular subscription — you license the modality or disease databases you need, per seat, on annual terms — which means the cost scales with how many corners of oncology you want covered.

The comparison worth making for a small company is not module price against retainer. It is what happens to either purchase in a quarter when nobody has spare hours: the subscription still bills and delivers nothing, the brief still arrives.

Using both

This is the pairing that composes most naturally of any on the site. Beacon covers the landscape at data depth for the people who want data; Prognyx covers the decision at reading depth for the people who want an answer. A company with a translational team and an unstaffed CI function has a genuine use for both.

How to decide in one question

Comparison last reviewed 1 September 2026. This page describes Beacon from its public product information and does not claim to be exhaustive; Beacon does not publish list pricing, and nothing here invents any. Prognyx has no affiliation with Beacon. Verify current scope and pricing with the vendor directly before any purchase decision. Names and trademarks referenced belong to their owners.